OPEN Health

Overview

OPEN Health is a London-headquartered global partner for healthcare communications, health economics and outcomes research (HEOR), market access consulting, and data analytics. Founded in 2011 and assembled into its current platform form between 2018 and 2023 through 6+ acquisitions, the company combines deep scientific expertise with strategic consulting to help pharma and biotech clients navigate market access, generate real-world evidence, and execute medical/commercial communications. Astorg Partners acquired OPEN Health in July 2022 via its Astorg VIII fund, and the company has grown from $193M revenue at acquisition to an estimated $260-280M in 2024. The workforce spans approximately 1,200-1,300 employees across 19 global locations.

Services & Capabilities

• HEOR & Market Access: Health economics modeling, outcomes research, systematic literature reviews, HTA dossier preparation, pricing & reimbursement strategy, value communication. Pharmerit International heritage gives the HEOR practice deep academic credibility.
• Medical Communications: Publication planning, medical education, KOL engagement, advisory boards, congress support. Peloton Advantage (acquired) is the medical communications backbone.
• Scientific Communications: Brand communications, omnichannel campaigns, promotional education, creative services. Bolstered by CM Group and Spirit acquisitions.
• Data Analytics & RWE: Real-world evidence generation, AI-powered KOL mapping (via fusion partnership), advanced analytics, systematic reviews, meta-analyses.
• Patient Engagement: Patient advocacy, patient-facing education, adherence programs.
• Commercial Strategy: Launch planning, market landscape assessments, competitive intelligence.

Acquisition History (Platform Assembly)

Acquisition	Focus	Contribution
Peloton Advantage	Medical communications	MedComms scale and client base
Pharmerit International	HEOR	Academic-grade HEOR and RWE capability
Spirit	Scientific communications	Creative and brand comms
ARK	Market access	European HTA expertise
CM Group	Communications	Integrated comms capacity
Acsel Health	Digital health	Technology and analytics

Competitive Position

OPEN Health competes at the intersection of HEOR, medical communications, and market access consulting — a space that has attracted significant PE interest. Key competitors include:

• Lumanity (Arsenal Capital) — Similar integrated HEOR + comms model; strong in rare disease
• Precision AQ (Blackstone) — Advertising/comms heritage with growing market access practice
• Trinity Life Sciences (Kohlberg) — Pure consulting/analytics with proprietary data assets
• IQVIA — Scale advantage with proprietary claims/Rx data; HEOR as part of broader CRO/data offering

Differentiation: OPEN Health’s core moat is the Pharmerit HEOR heritage integrated with a full-spectrum medical communications capability. This allows end-to-end work from evidence generation through HTA submission to KOL engagement and publication — a workflow competitors typically cannot deliver under one roof.

Vulnerabilities:

• No proprietary data assets (unlike IQVIA or Trinity), making the business more people-dependent
• Post-acquisition integration complexity from assembling 6+ firms; approximately 9% headcount reduction reported during integration
• CEO transition mid-hold period introduces execution risk

Recent Developments

• March 2025: Matt D’Auria appointed CEO, succeeding prior leadership. D’Auria brings experience from Healthcare Consultancy Group, Syneos Health, and AstraZeneca. Signals a push toward more commercial/enterprise growth orientation.
• February 2026: Significant leadership additions — Global President of Enterprise Growth, Global Head of Brand, Senior Client Partner, and EVP of Promotional Education. Indicates preparation for either accelerated organic growth or exit positioning.
• June 2024: Announced fusion partnership for AI-powered KOL mapping and analytics, representing the company’s primary AI/technology strategy.
• May 2024: Astorg VIII fund closed, starting the clock on a 2026-2028 exit window.
• January 2025: EU HTA Regulation Joint Clinical Assessments (JCAs) went live, creating a significant demand tailwind for OPEN Health’s European HTA capabilities.

Client & Partner Ecosystem

• Clients: 49 of top 50 pharma companies (Medical Affairs, Commercial, HEOR/Market Access teams). Deep relationships across GSK, Novartis, ViiV Healthcare, and broad mid-cap biotech.
• Technology Partners: fusion (AI analytics and KOL mapping)
• Referral Network: Health authorities, HTA bodies (NICE, G-BA, HAS), academic institutions for HEOR collaboration

Technology Platform

No proprietary technology platform. Technology strategy executed through partnerships (primarily fusion for AI/ML analytics and KOL mapping). Internal tooling for project management and data analysis but no named SaaS products. This is both a strategic gap (vs. data-rich competitors) and a feature (asset-light, people-first model).

Sources

• OPEN Health Website
• Astorg Acquisition Announcement
• Houlihan Lokey Interview
• LinkedIn
• PMLiVE
• raw/research/open-health.pplx.md